CO4960666A1 - Complejo de neutralizacion de cargas con arginilo de epro- sartan y un procedimiento para su produccion y formulacion - Google Patents

Complejo de neutralizacion de cargas con arginilo de epro- sartan y un procedimiento para su produccion y formulacion

Info

Publication number
CO4960666A1
CO4960666A1 CO98045455A CO98045455A CO4960666A1 CO 4960666 A1 CO4960666 A1 CO 4960666A1 CO 98045455 A CO98045455 A CO 98045455A CO 98045455 A CO98045455 A CO 98045455A CO 4960666 A1 CO4960666 A1 CO 4960666A1
Authority
CO
Colombia
Prior art keywords
thiophene
methylene
butyl
imidazol
methyl
Prior art date
Application number
CO98045455A
Other languages
English (en)
Spanish (es)
Inventor
R Gudipati Manga
M Venkatesh Gopadi
R Palepu Nageswara
John M Jushchyshyn
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO4960666A1 publication Critical patent/CO4960666A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CO98045455A 1997-08-06 1998-08-10 Complejo de neutralizacion de cargas con arginilo de epro- sartan y un procedimiento para su produccion y formulacion CO4960666A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5499097P 1997-08-06 1997-08-06

Publications (1)

Publication Number Publication Date
CO4960666A1 true CO4960666A1 (es) 2000-09-25

Family

ID=21994861

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98045455A CO4960666A1 (es) 1997-08-06 1998-08-10 Complejo de neutralizacion de cargas con arginilo de epro- sartan y un procedimiento para su produccion y formulacion

Country Status (26)

Country Link
EP (1) EP1027047B1 (enExample)
JP (1) JP4463975B2 (enExample)
KR (1) KR100508044B1 (enExample)
CN (1) CN1276724A (enExample)
AR (1) AR015930A1 (enExample)
AT (1) ATE341325T1 (enExample)
AU (1) AU739295B2 (enExample)
BR (1) BR9811926A (enExample)
CA (1) CA2299470C (enExample)
CO (1) CO4960666A1 (enExample)
CY (1) CY1105851T1 (enExample)
CZ (1) CZ296274B6 (enExample)
DE (1) DE69836095T2 (enExample)
DK (1) DK1027047T3 (enExample)
ES (1) ES2273433T3 (enExample)
HU (1) HUP0201624A3 (enExample)
IL (1) IL134378A (enExample)
NO (1) NO317771B1 (enExample)
NZ (1) NZ502644A (enExample)
PL (1) PL198875B1 (enExample)
PT (1) PT1027047E (enExample)
SA (1) SA98190592B1 (enExample)
TR (1) TR200000350T2 (enExample)
TW (1) TW570921B (enExample)
WO (1) WO1999007365A1 (enExample)
ZA (1) ZA987018B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
SK286859B6 (sk) * 1999-04-28 2009-06-05 Takeda Pharmaceutical Company Limited Farmaceutický prípravok na predchádzanie, liečenie alebo inhibovanie vývoja jednoduchej retinopatie alebo predproliferačnej retinopatie
RS20050590A (sr) 2003-01-31 2007-09-21 Sankyo Company Limited, Lek za profilaksu i tretman arterioskleroze i hipertenzije
NO323391B1 (no) 2005-09-28 2007-04-23 Hts Hans Torgersen & Sonn As Barnepose
US20100278909A1 (en) * 2007-06-06 2010-11-04 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
JP5476782B2 (ja) * 2009-04-21 2014-04-23 大正製薬株式会社 アルギニン含有錠剤の製造方法
JP5446716B2 (ja) * 2009-10-21 2014-03-19 大正製薬株式会社 アルギニン及びカルニチン含有錠剤の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
JP3398379B2 (ja) * 1990-12-14 2003-04-21 スミスクライン・ビーチャム・コーポレイション アンジオテンシンii受容体遮断組成物
AU9137791A (en) * 1990-12-14 1992-07-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
DE4208052A1 (de) * 1992-03-13 1993-09-16 Bayer Ag Imidazolyl substituierte phenylessigsaeureamide
FR2688781B1 (fr) * 1992-03-23 1994-07-01 Sanofi Elf Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
DE4210787A1 (de) * 1992-04-01 1993-10-07 Bayer Ag Cycloalkyl- und Heterocyclyl substituierte Imidazolylpropensäurederivate
JPH0841053A (ja) * 1994-07-28 1996-02-13 Nkk Corp ヘテロアリールアルキル基を有するピリミジン誘導体及 び該誘導体を有効成分として含有するアンジオテンシン ii拮抗剤
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
SK77498A3 (en) * 1995-12-14 1999-01-11 Merck & Co Inc Nonpeptide derivatives, pharmaceutical composition containing them and their use

Also Published As

Publication number Publication date
JP4463975B2 (ja) 2010-05-19
PT1027047E (pt) 2007-01-31
ATE341325T1 (de) 2006-10-15
IL134378A0 (en) 2001-04-30
NO20000577L (no) 2000-02-29
WO1999007365A1 (en) 1999-02-18
TW570921B (en) 2004-01-11
ZA987018B (en) 1999-02-08
PL341562A1 (en) 2001-04-23
DE69836095T2 (de) 2007-04-12
CA2299470C (en) 2010-01-26
KR20010022582A (ko) 2001-03-26
CA2299470A1 (en) 1999-02-18
AR015930A1 (es) 2001-05-30
ES2273433T3 (es) 2007-05-01
HK1031688A1 (en) 2001-06-22
NZ502644A (en) 2002-03-01
JP2001513498A (ja) 2001-09-04
CY1105851T1 (el) 2011-02-02
HUP0201624A3 (en) 2003-03-28
BR9811926A (pt) 2000-08-22
EP1027047A4 (en) 2002-09-18
DE69836095D1 (de) 2006-11-16
PL198875B1 (pl) 2008-07-31
KR100508044B1 (ko) 2005-08-17
DK1027047T3 (da) 2007-01-29
IL134378A (en) 2004-02-19
CN1276724A (zh) 2000-12-13
NO20000577D0 (no) 2000-02-04
TR200000350T2 (tr) 2000-12-21
CZ2000406A3 (cs) 2000-09-13
HUP0201624A2 (hu) 2002-12-28
EP1027047B1 (en) 2006-10-04
CZ296274B6 (cs) 2006-02-15
NO317771B1 (no) 2004-12-13
SA98190592B1 (ar) 2006-06-20
AU8768898A (en) 1999-03-01
AU739295B2 (en) 2001-10-11
EP1027047A1 (en) 2000-08-16

Similar Documents

Publication Publication Date Title
BR9810487A (pt) Processo para a produção de um produto detergente granular.
DE69807104D1 (de) Formulierungen mit gesteuerter freisetzung
ES2171471T3 (es) Sistema para la administracion oral de desferrioxamina.
NO985938L (no) Anordning for topikal behandling av akne og fremgangsmÕte ved fremstilling derav
BR0013720A (pt) Formulação em pelota de liberação controlada
IL111647A0 (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles, their preparation and pharmaceutical compositions containing them
CY1107438T1 (el) Παραγωγα καρβοξυλικου οξεος, τα οποια παρεμποδιζουν την συνδεσιν ιντεγκρινων εις τους υποδοχεις των
ES8504110A1 (es) "procedimiento para preparar nonapeptidos y decapeptidos analogos a lhrh"
NO175240C (no) Fremgangsmåte for fremstilling av et langsomt frigivende farmasöytisk preparat som omfatter sekundære granuler
IS2354B (is) Lyfjasamsetning sem mögulegt er að hleypa
MX354218B (es) Granulos estables y durables con agentes activos.
CO4960666A1 (es) Complejo de neutralizacion de cargas con arginilo de epro- sartan y un procedimiento para su produccion y formulacion
BR0215175A (pt) Métodos para a granulação úmida de azitromicina
TR200103427T2 (tr) Integrinlerin reseptörlerine bağlanmasını engelleyen propanoik asit türevleri.
NO20021086L (no) Anordning for forsinket frigivelse av anti-aknemiddel
BR0008713A (pt) Processos para preparar formulações ecomposições farmacêuticas orais com ecb
BR9609411A (pt) Peptìdeo, composição, vacina, e, processos para inocular um animal com a vacina, afetar uma ou mais caracterìsticas reprodutivas ou comportamentais de um animal e imunocastrar um porco.
BR0013283A (pt) Agente farmacêutico que compreende um derivado de benzamida como ingrediente ativo
BR9909121A (pt) Composto, composição farmacêutica, e, processos para inibir a liberação de hormÈnio de luteinização (lh) em um mamìfero em necessidade de tal tratamento e para preparar um composto
BR9909080A (pt) Composto, composição farmacêutica para inibir a liberação de lh, processo de inibir a liberação de lh em um mamìfero em necessidade de tal tratamento, processo para preparar um composto
ES8506599A1 (es) Un procedimiento para preparar heptapeptidos y hexapeptidos ciclicos antagonistas de la vasopresina
BR0012939A (pt) Tablete de uma composição particulada compactada, e, processos para produzir grânulos, e para produzir um tablete
MX9304776A (es) Nuevo proceso diseñado para la alquilacion de pro uctos aromaticos.
JPS5282715A (en) Long acting drug composition
Broulík et al. The role of calcitonin in hypocalcemia in acute experimental pancreatitis